Mitsubishi Tanabe hit by new suspension over quality control worries
This article was originally published in Scrip
Mitsubishi Tanabe Pharma (MTP) has been ordered to suspend operations at a production plant in Japan for 10 days in relation to product quality control problems at the site identified earlier this year.
You may also be interested in...
New potential topical therapy in dermatitis space set to move towards Japan approval submission based on positive new results.
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.